Abstract
We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011–2014 but increased during 2015–2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5–64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution. In 2018, serotypes in the 15-valent and 20-valent PCVs represented one third of cases in children <5 years of age and two thirds of cases in persons >65 years of age. Non-PCV13 serotype increases reduced the overall effect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.
Highlights
Introduction ofPCV10 or in 2018 includedCZ recommended and PCV13 in PPV23 and used in2010, 3+1 doses in 2010, 2+1 PPV23 (11%)doses in 2010, 2+1 doses FI
In the 65 years of age, excluding France [20]
This study of 13 sites in Europe enabled us to estimate the overall effect of 8 years of the childhood PCV10 and PCV13 program on IPD in the age groups targeted directly and indirectly by vaccination
Summary
SpIDnet collected IPD data from 13 sites across 10 countries: the Czech Republic, Denmark, England, Finland, France, Ireland, the Netherlands, Norway, Scotland, Sweden, and Spain (the Madrid, Catalonia, and Navarra regions). CAT, Catalonia; CZ, Czech Republic; DK, Denmark; ECDC, European Centre for Disease Prevention and Control; EN, England; FI, Finland; FR, France; IE, Ireland; MAD, Madrid; NAV, Navarra; NL, the Netherlands; NOR, Norway; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; SC, Scotland; SE, Sweden; SpIDnet, Streptococcus pneumoniae Invasive Disease network.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
